期刊文献+

氟康唑对HIV感染者口腔白色念珠菌抗真菌后效应的体外研究

In vitro Post-antifungal Effect of Fluconazole against Oral Candida Albicans Isolates in HIV Disease
下载PDF
导出
摘要 目的评估氟康唑体外最小抑菌浓度(minimum inhibitory concentration,MIC)和检测暴露于小剂量氟康唑后白色念珠菌口腔分离株的抗真菌后效应(post-antifungal effect,PAFE)。方法将白色念珠菌标准株和10株临床分离株分别暴露于4×MIC和6×MIC的氟康唑后,使用自动化的浊度分析测量法检测白色念珠菌PAFE的存在。结果由4×MIC和6×MIC的氟康唑在RPMI 1640液体培养基中诱导的白色念珠菌标准株产生的PAFE平均持续时间分别为0.12 h和3.14 h;诱导的10株临床分离株产生的PAFE持续时间平均分别为(0.19±0.24)h和(2.08±0.25)h。其中6×MIC氟康唑的PAFE在临床菌株内差异有统计学意义(P=0.000),而4×MIC氟康唑的PAFE在临床菌株内差异没有统计学意义(P=0.529)。结论氟康唑能有效地抑制白色念珠菌的生长,在白色念珠菌中引起PAFE。 Objective To evaluate the minimum inhibitory concentration (MIC) and measure post-antifungal effect (PAFE) of oral Candida albicans isolates following limited exposure to flueonazole. Methods Ten oral isolates of C. albicans were examined for the presence of the PAFE following limited exposure to fluconazole (4 x MIC and 6 x MIC), respectively, measured using automated turbidometry. Results The duration of the mean PAFE for C. albican ATCC 90031 induced by fluconazole at concentrations of 4 x MIC and 6 x MIC in RPMI medium were 0.12 h and 3.14 h respec- tively, compared with (0.19 ± O. 24) h and (2.08 ± 0.25 ) h respectively, for all 10 isolates of C. albicans. Significant intra-strain differences in PAFE were observed after exposure to 6 x MIC flueonazole ( P = O. 000), but not for 4 x MIC fluconazole ( P = 0. 529 ). Conclusion Flueonazole can effectively perturb C. albicans growth and elicited a peired of PAFE in C. albicans.
出处 《广东牙病防治》 2011年第5期253-256,共4页 Journal of Dental Prevention and Treatment
基金 广东省医学科学技术研究基金(B2007025 A2008109)
关键词 氟康唑 抗真菌后效应 白色念珠菌 氟康唑/药理学 白色念珠菌/药物作用 Fluconazole Post antifungal effect Candida albicans Fluconazole/pharmacology Candida albicans/ drug effects
  • 相关文献

参考文献13

  • 1Samaranayake LP, Holmstrup P. Oral candidiasis and human immunodeficiency virus infection. J Oral Pathol Med, 1989,18 ( 10 ) :554- 564.
  • 2Arendorf TM, Bredekamp B,. Cloete C, et al. Oral manifestations of HIV infection in 600 South African patients. J Oral Pathol Med, 1998,27(4) : 176-179.
  • 3Samaranayake LP, Lamey PJ. Oral candidosis: clinicopathological aspects. Dent Update, 1988,15 (6) :227-228,230-231.
  • 4Samaranayake LP. Oral mycoses in HIV infection. Oral Surg Oral Med Oral Pathol, 1992,73 ( 2 ) : 171-180.
  • 5Krcmery V, Barnes AJ. Non-albicans Candida spp. causing fungaemia pathogenicity and antifungal resistance. J Hosp Infect, 2002,50 (4) :243-260.
  • 6Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin M icrobiol Rev, 2007,20(2) : 133-163.
  • 7Craig WA, Gudmundsson S. The postantibiotic effect// Lorian V. Antibiotics in laboratory medicine. Bahimore: Williams & Wilkins, 1996 : 296 -329.
  • 8Mcginnis MR, Rinaldi MG. Antifungal drugs: mechanisms of action drug resistance, susceptibility testing and assays of activity in biologi cal fluids//Lorian V. Antibiotics in laboratory medicine. Baltimore Williams & Wilkins, 1996 : 176-211.
  • 9Scalarone GM, Mikami Y, Kurita N, et al. Turhidometric characterization of the postantifungal effect: comparative studies with amphoteficin B, 5-fluorocytosine and miconazole on C albicans. Mycoses, 1991,34 ( 7/8 ) :297-302.
  • 10Ellepola ANB, Samaranayake LP. Oral candidal infections and antimycotics. Crit Rev Oral Biol Med, 2000,11 (2) :172-198.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部